FTC re­view pe­ri­ods end for Ab­b­Vie-Im­muno­Gen $10.1B deal and $4B BMS-Rayze­Bio buy­out

Ab­b­Vie moved ahead with its $10.1 bil­lion ac­qui­si­tion of an­ti­body-drug con­ju­gate biotech Im­muno­Gen, while Bris­tol My­ers Squibb’s big ac­qui­si­tion of ra­dio­phar­ma­ceu­ti­cals biotech Rayze­Bio is like­ly …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.